Seaport Therapeutics, Inc. SPTX
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -1.21%
- 1 year
- -1.21%
- Open
- 20.96
- Prev close
- 21.10
- Mkt cap
- 1.05B
- Vol
- 549.19K
- Avg vol
- 203.02K
- EPS
- -5.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.00
- High
- 21.16
- Forward P/E
- -7.60
- Beta
- 0.00
- Short ratio
- 12.17
- Inst. own
- 70.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 21.25
- 200-d avg
- 20.13
- 1y target
- 37.00
News
3 days ago seekingalpha.com
Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discount
Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD markets. SPTX maintains a cash runway into 2029, with $427.3…
2 weeks ago benzinga.com
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
-
2 weeks ago benzinga.com
Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $28.
3 weeks ago gurufocus.com
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran
3 weeks ago businesswire.com
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.
3 weeks ago gurufocus.com
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
[url="]Seaport Therapeutics, Inc.[/url] (Nasdaq: SPTX) (âSeaportâ or the âCompanyâ), a clinical-stage therapeutics company developing novel neuropsychia
-
3 weeks ago benzinga.com
Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13
Congress is taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1 program and provides detailed…
3 weeks ago businesswire.com
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
3 weeks ago businesswire.com
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.
3 weeks ago businesswire.com
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON--(BUSINESS WIRE)--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance.
4 weeks ago defenseworld.net
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up – Should You Buy?
Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $18.69, but opened at $20.12. Seaport Therapeutics…
1 month ago defenseworld.net
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Down – What’s Next?
Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) shares gapped down before the market opened on Wednesday. The stock had previously closed at $19.64, but opened at $18.85. Seaport…
1 month ago defenseworld.net
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57
Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the firm, MarketBeat.com…
1 month ago benzinga.com
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.
-
1 month ago benzinga.com
Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46
Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Strong Buy rating and announces Price Target of $46.
1 month ago businesswire.com
Seaport Therapeutics to Participate in September Investor Conferences
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
1 month ago seekingalpha.com
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
1 month ago gurufocus.com
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran
1 month ago businesswire.com
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.
-
1 month ago benzinga.com
Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey…
1 month ago businesswire.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.
-
2 months ago benzinga.com
Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32
Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $32.
2 months ago 247wallst.com
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
2 months ago defenseworld.net
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High – Here’s What Happened
Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $25.07 and last traded at $24.40, with a…
2 months ago seekingalpha.com
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation
Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
3 months ago gurufocus.com
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
[url="]Seaport Therapeutics, Inc.[/url], (Nasdaq: SPTX) (âSeaportâ or the âCompanyâ), a clinical-stage therapeutics company that is inventing and develo
-
3 months ago benzinga.com
Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate
Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(1.78) per share which missed the analyst consensus estimate of $(0.65) by 173.85 percent. This is a 72.19 percent increase over…
3 months ago businesswire.com
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
-
3 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $50.
-
4 months ago benzinga.com
Seaport Therapeutics Q1 EPS $(10.34) Misses $(9.48) Estimate
Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(10.34) per share which missed the analyst consensus estimate of $(9.48) by 9.07 percent.
-
5 months ago benzinga.com
Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35
Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $35.
-
5 months ago benzinga.com
Leerink Partners Initiates Coverage On Seaport Therapeutics with Outperform Rating, Announces Price Target of $35
Leerink Partners analyst Marc Goodman initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Outperform rating and announces Price Target of $35.
-
5 months ago benzinga.com
JP Morgan Initiates Coverage On Seaport Therapeutics with Overweight Rating, Announces Price Target of $42
JP Morgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Overweight rating and announces Price Target of $42.
-
5 months ago benzinga.com
Stifel Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $30
Stifel analyst Paul Matteis initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $30.